GLP-1 Products have achieved massive growth: By the end of 2024, these GLP-1 products had a cumulative $71 billion in U.S
Some can handle weeks outside the fridge after first use
In addition to nausea and vomiting, people taking GLP-1 drugs can experience altered bowel habits due to the slowed motility of the gut
From combination therapies that preserve muscle mass, to oral agents breaking bioavailability barriers, and dual-agonists redefining treatment strategieseach advancement marks a critical step forward for the millions living with obesity and type 2 diabetes
doi: 10.1016/S2213-8587(17)30013-X 221 ArodaVRRosenstockJTerauchiYAltuntasYLalicNMMorales VillegasECet al
"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept." Cell Metabolism